Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 16

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 16
---
 will not receive any proceeds                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 from the sale of shares of Common Stock that may be sold from time to time pursuant to this prospectus; however, we will receive proceeds                                                                                                                                                                                                                                                                                                                                                                                                                                                               
 from any cash exercise of the Common Warrants. See “Use of Proceeds.” We intend to use the proceeds from any cash exercise                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 of the Common Warrants for working capital purposes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Plan of Distribution                                       |     | The Selling Stockholders named in this prospectus, or their pledgees, donees, transferees, distributees, beneficiaries or other successors-in-interest, may offer or sell the shares of Common Stock offered hereby from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The Selling Stockholders may also resell the shares of Common Stock to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions. |

| Risk Factors |     | See “Risk Factors” beginning on page 8 of this prospectus and the other information included in this prospectus for a discussion of factors you should carefully consider before investing in our securities. |

| Nasdaq Capital Market 
 trading symbol        |     | Our Common Stock is listed on the Nasdaq Capital Market under the symbol “BIAF.” Our Tradeable Warrants are listed on the Nasdaq Capital Market under the symbol “BIAFW.” |

The information above is based on 18,248,623
shares of Common Stock outstanding as of April 10, 2025, and excludes, as of that date the following:

| ● | 12,873,602                                                                                                                             
 shares of Common Stock issuable upon the exercise of outstanding warrants with a weighted                                              
 average exercise price equal to $2.74 per share;                                                                                       |
| ● | 304,125 shares of Common Stock issuable upon                                                                                           
 the exercise of stock options issued under our equity incentive plans with a weighted average exercise price equal to $6.95 per share; 
 and                                                                                                                                    |
| ● | 1,480,208 shares of our Common Stock that are                                                                                          
 reserved for equity awards that may be granted under our 2024 Equity Incentive Plan.                                                   |

| 5 |

<div align='center'>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

Certain statements in this prospectus may contain
“forward-looking statements